References
1. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G.
Oral anticoagulant therapy - Antithrombotic therapy and prevention of
thrombosis, 9th ed: American College of Chest Physicians evidence-based
clinical practice guidelines. Chest . 2012;141:e44S-e88S.
2. Ufer M. Comparative Pharmacokinetics of Vitamin K Antagonists.Clin Pharmacokinet . 2005;44:1227-1246.
3. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of
warfarin and its drug and food interactions. Arch Intern Med .
2005;165:1095-1106.
4. Beinema M, Brouwers JRBJ, Schalekamp T, Wilffert B. Pharmacogenetic
differences between warfarin, acenocoumarol and phenprocoumon.Thromb Haemost . 2008;100:1052-1057.
5. Desai CS, Martin SS, Blumenthal RS. Non-cardiovascular effects
associated with statins. BMJ . 2014;349:1-10.
6. Sirtori CR. The pharmacology of statins. Pharmacol Res .
2014;88:3-11.
7. Hellfritzsch M, Lund LC, Ennis Z, et al. Ischemic Stroke and Systemic
Embolism in Warfarin Users With Atrial Fibrillation or Heart Valve
Replacement Exposed to Dicloxacillin or Flucloxacillin. Clin
Pharmacol Ther . 2020;107:607-616.
8. Lexicomp® Drug Interactions - UpToDate.
9. Drug Interactions search - MICROMEDEX.
10. Interaktionsdatabasen.dk.
11. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for
systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.Rev Esp Nutr Humana y Diet . 2016;20:148-160.
12. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for
systematic review and meta-analysis protocols (prisma-p) 2015:
Elaboration and explanation. BMJ . 2015;350:1-25.
13. Andersson ML, Mannheimer B, Lindh JD. The effect of simvastatin on
warfarin anticoagulation: a Swedish register-based nationwide cohort
study. Eur J Clin Pharmacol . 2019;75:1387-1392.
14. Kamali F, Hickmott H, Wynne H. The effect of simvastatin
co-medication on warfarin anticoagulation response and dose
requirements. Thromb Haemost . 2003;89:949-950.
15. Simonson SG, Martin PD, Mitchell PD, Lasseter K, Gibson G, Schneck
DW. Effect of rosuvastatin on warfarin pharmacodynamics and
pharmacokinetics. J Clin Pharmacol . 2005;45:927-934.
16. Stern R, Abel R, Gibson GL BJ. Atorvastatin Does Not Alter the
Anticoagulant Activity of Warfarin. J Clin Pharmacol .
1997;37:1062-1064.
17. van Rein N, Biedermann JS, Bonafacio SM, Kruip MJHA, van der Meer
FJM, Lijfering WM. Statin use decreases coagulation in users of vitamin
K antagonists. Eur J Clin Pharmacol . 2016;72:1441-1447.
18. Schelleman H, Bilker WB, Brensinger CM, Wan F, Yang YX, Hennessy S.
Fibrate/Statin Initiation in Warfarin Users and Gastrointestinal
Bleeding Risk. Am J Med . 2010;123:151-157.
19. Engell AE, Svendsen ALO, Lind BS, et al. Drug‐drug interaction
between warfarin and statins: A Danish cohort study. Br J Clin
Pharmacol . Published online 2020:1-6.
20. Hansen PW, Clemmensen L, Sehested TSG, et al. Identifying Drug-Drug
Interactions by Data Mining: A Pilot Study of Warfarin-Associated Drug
Interactions. Circ Cardiovasc Qual Outcomes . 2016;9:621-628.
21. Sun Q, Welsh KJ, Bruns DE, Sacks DB, Zhao Z. Inadequate reporting of
analytical characteristics of biomarkers used in clinical research: A
threat to interpretation and replication of study findings. Clin
Chem . 2019;65:1554-1562.
22. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Effects of the
antifungal agents on oxidative drug metabolism. Clinical relevance.Clin Pharmacokinet . 2000;38:111-180.
23. O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A
reductase inhibitor, improves endothelial function within 1 month.Circulation . 1997;95:1126–1131.
24. Wiklund O, Pirazzi C, Romeo S. Monitoring of lipids, enzymes, and
creatine kinase in patients on lipid-lowering drug therapy. Curr
Cardiol Rep . 2013;15:397.